In the prior laser group , a progressive BCVA improvement ( +6.0 letters ) and CRST reduction ( -142.7 m ) at month 36 were observed after allowing ranibizumab during the extension study , with a median of 4.0 injections ( mean , 6.5 injections ) from months 12 to 35 .